Gilead Sciences Inc
(WBO:GILD)
€
82.34
-0.83 (-1%)
Market Cap: 103.30 Bil
Enterprise Value: 122.22 Bil
PE Ratio: 109.56
PB Ratio: 6.12
GF Score: 77/100 
Gilead Sciences Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021 / 06:00PM GMT
Release Date Price:
€56.59
(+0.93%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Okay. Good afternoon. And welcome to the final day of the BofA Healthcare Conference, Virtual Vegas, as it were. My name is Geoff Meacham. I'm a senior biopharma analyst here at BofA. And I have Jason Zemansky from my team with me as well. And we're thrilled to have CFO, Andy Dickinson from Gilead. Andy, welcome.
Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO
Thank you. Thanks for having me. Appreciate it once again.
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Yes. So what we'll do is, we'll do some questions here with Andy. We won't get into anything post the quarter. Obviously, we've talked about that a week or so ago. But let's get right into it, Andy.
Questions & Answers
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
When you think about the HIV business. It's a flagship
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers